ELTX Elicio Therapeutics
- 6.250
- -0.190-2.95%
Elicio Therapeutics News
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Elicio Therapeutics Advances ELI-002 and Secures Funding
Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Express News | Elicio Therapeutics Announces Completion of Phase 2 Amplify-7P Study Enrollment
Express News | Elicio Therapeutics Inc: Expects Current Cash and Cash Equivalents to Support Operations Into Q2 of 2025
Express News | Elicio Therapeutics Q3 2024 GAAP EPS $(1.39) Misses $(0.73) Estimate
Elicio Therapeutics Reports Q3 EPS ($1.39), Consensus (73c)
Elicio Therapeutics Files to Sell 3.44M Shares of Common Stock for Holders
Express News | Elicio Therapeutics Inc Files for Offering of up to 3.4 Mln Shares by the Selling Stockholder - SEC Filing
Elicio Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Elicio Therapeutics Q3 Income From Operations USD -10.344 Million
Press Release: Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $9
Elicio Therapeutics Presents Updated Preliminary Results From AMPLIFY-7P
Express News | Elicio Therapeutics Shares ELI-002 Phase 1 Data At SITC 2024; Preliminary Results Show Dose-Dependent T Cell Responses Targeting KRAS Mutations And Link To Disease-Free Survival
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
JonesTrading Initiates Elicio Therapeutics(ELTX.US) With Buy Rating, Announces Target Price $9
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Express News | Elicio Therapeutics: Appoints Robert Connelly as Principal Financial Officer
No Data